Connect Biopharma Holdings Limited Ordinary Shares (CNTB)
How it compares with the broader market is one of its lowest-scoring factors; business numbers score is on the low side; price trend is one of its lowest-scoring factors.
CNTB scores higher than 5% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Connect Biopharma Holdings Limited Ordinary Shares (CNTB) scores 18 out of 100 on the Market Census six-factor composite, which puts it at the Low score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.14× 30-day average
- 52-week range
- 0.85 – 3.82
- Market cap
- $80.61M
- Earnings date
- 10 Nov 2026
- Volume
- 1,054,626
- Avg. volume (30d)
- 7,684,998
- Open
- 0.87
- Previous close
- 0.88
- Day's range (regular session)
- 0.87 – 0.93
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.03
- P/E (TTM)
- —
- EPS (TTM)
- -1.20
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for CNTB
- 2 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for CNTB. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about CNTB right now
Connect Biopharma Holdings Limited Ordinary Shares (CNTB) currently scores 18/100 on the Market Census six-factor composite, at the Low score level. CNTB is -1.21% on the day and -6.15% over five sessions as of the most recent tick. Low is the lowest level. Much of CNTB's data reads poorly right now. Market Census does not tell you to short it; the level only describes the data. CNTB's strongest factor is insider trades at 50/100 — a fairly good read on insider buying and selling. Insider filings do not lean toward buying or selling right now — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See CNTB in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent CNTB news
Latest headlines that name Connect Biopharma, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Connect Biopharma COPD Study Shows 81% Cut in Treatment FailuresYahoo
- Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 ProgramYahoo
- Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations TranscriptSeekingAlpha
- Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 InflammationYahoo
- Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?Yahoo
We hide 5 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to CNTB’s 18, all within 1 point.
Sorted by closeness to CNTB’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.